One of the UK’s leading daily newspapers, The Telegraph, reports on the partnership between CEPI and Tiba Biotech and that CEPI has invested in a project to develop cheaper, more effective shots with fewer side effects.
CEPI Partners with Tiba Biotech to Evaluate Next-Generation RNA Vaccine Platform Technology to Respond to ‘Disease X’
January 12, 2023
As the first award to be granted under CEPI’s innovation program, CEPI will provide US$2 million to advance Tiba Biotech’s novel RNA nanoparticle delivery platform, RNABL™.
Multi-institute Research on Nasal Delivery of Tiba’s RNABL™ Nanoparticles Published in SCIENCE IMMUNOLOGY
December 12, 2022
In a study published in Science Immunology, University of Minnesota researchers in collaboration with colleagues at Tiba Biotech and Emory University, demonstrated that nasal delivery of Tiba's RNABL vaccine induced adaptive immune responses in the respiratory tracts of mice.
Tiba Biotech announces the extension of an earlier CIVICs initiative with scientists from the University of Minnesota and Emory University to study the level and duration of protection of Tiba’s next-generation RNA vaccines.
(Full Report) Channel Ten Sydney TV Reports on Private/Public Initiative to Address Emerging Animal Disease Threats in the Region
September 29, 2022
Channel Ten Sydney evening news opens with this segment featuring Peter McGrath, Tiba Biotech’s co-founder and CFO. A native Australian, McGrath has returned to Australia and is working closely with NSW to manage this unique private/public initiative to address the emerging animal disease threats in the region.
(Exclusive) A Foot and Mouth Disease mRNA Vaccine Deal Has Been Signed Between the NSW Government and US Company Tiba Biotech
September 28, 2022
TV Channel 10 News Sydney provides this first exclusive from Down Under regarding Tiba Biotech and the Australian State of New South Wales partnership to address emergency animal disease threats.
Tiba Biotech and the Australian State of New South Wales Enter Partnership to Address Emergency Animal Disease Threats
September 27, 2022
Tiba Biotech, a preclinical biopharmaceutical company, today announced it has entered into a five-year, multi-million US dollar agreement with the Australian state government of New South Wales (NSW) to develop next-generation mRNA vaccines against emergency animal diseases that threaten Australia’s livestock industry and domestic food security.
Tiba Biotech announces a new collaboration with leading researchers at the Cummings School of Veterinary Medicine of Tufts University to develop next generation vaccines against emerging tick-borne diseases (TBDs).
Tiba Biotech receives a Notice of Intent from NIAID to fund a Phase I SBIR to develop a novel RNA vaccine against a deadly tick bourn disease with the Cummings School for Veterinary Medicine
Tiba Biotech receives a Phase I SBIR grant from NIAID to develop a multi-antigen RNA-based vaccine against the highly pathogenic H7N9 strain of influenza virus.
Keep connected with us
© 2024 Tiba Biotech LLC. All rights reserved